NCT07136389 - Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

November 1, 2026

Conditions

Systemic Lupus Erthematosus

Interventions

DRUG

BCD-256

Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

DRUG

BCD-256

Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

DRUG

BCD-256

Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

DRUG

Divozilimab

Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously

DRUG

BCD-256

Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

Trial Locations (1)

RECRUITING

"Multidisciplinary medical center for adults and children №157", Saint Petersburg